TNFRSF10A and pancreatic neoplasm: This way of potentially improving the therapeutic efficacy of TRAIL by using TRAIL-receptor specific agents is of particular interest for pancreatic cancer, as previous studies have shown that pancreatic tumour cells preferentially use TRAIL-R1 to execute TRAIL-induced apoptosis [39, 40].